The potency of SCO as a PPARγ agonist indicates that further investigation is necessary to determine its efficacy as a complementary therapy in the prevention and/or treatment of T2DM; SCO may have some of the insulin-sensitizing benefits of TZDs without the unfavorable side effects. This evidence concerns the gene PPARG and type 2 diabetes mellitus.